Discovery of indoline derivatives that inhibit esophageal squamous cell carcinoma growth by Noxa mediated apoptosis

被引:6
|
作者
Fu, Dong-Jun [1 ,2 ,3 ]
Li, Miaomiao [1 ]
Zhang, Sai-Yang [1 ,4 ]
Li, Jiang-Feng [1 ]
Sha, Beibei [1 ]
Wang, Longhao [1 ]
Zhang, Yan-Bing [2 ,3 ]
Chen, Ping [1 ,4 ]
Hu, Tao [1 ]
机构
[1] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, New Drug Res & Dev Ctr, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[3] Collaborat Innovat Ctr New Drug Res & Safety Eval, Zhengzhou 450001, Henan, Peoples R China
[4] Zhengzhou Univ, Henan Inst Adv Technol, Zhengzhou 450001, Henan, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Indoline; Esophageal squamous cell carcinoma; Cell growths in vitro and in vivo; Noxa-dependent apoptosis; ANTIPROLIFERATIVE ACTIVITY; DITHIOCARBAMATE HYBRIDS; BIOLOGICAL EVALUATION; DESIGN; POTENT; AGENTS; CANDIDATE; RESIDUES;
D O I
10.1016/j.bioorg.2019.103190
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of novel indoline derivatives were synthesized and evaluated for antiproliferative activity against four selected cancer cell lines (Hela, A549, HepG2 and KYSE30). Among them, compound 20 displayed the potent inhibition activity against esophageal cancer cells (Kyse30, Kyse450, Kyse510 and EC109). Cellular mechanism studies in esophageal squamous cell carcinoma (ESCC) cells elucidated compound 20 inhibited cell growths in vitro and in vivo, reduced colony formation, arrested cell cycle at M phase, and induced Noxa-dependent apoptosis in ESCC. Importantly, compound 20 was identified as a novel Noxa mediated apoptosis inducer. These results suggested that compound 20 might be a promising anticancer agent with potential for development of further clinical applications.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Immunotherapy for esophageal squamous cell carcinoma : a review
    Mimura, Kosaku
    Yamada, Leo
    Ujiie, Daisuke
    Hayase, Suguru
    Tada, Takeshi
    Hanayama, Hiroyuki
    Min, Aung Kyi Thar
    Shibata, Masahiko
    Momma, Tomoyuki
    Saze, Zenichiro
    Ohki, Shinji
    Kono, Koji
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2018, 64 (02) : 46 - 53
  • [42] The role of microRNA in esophageal squamous cell carcinoma
    Kazuto Harada
    Yoshifumi Baba
    Takatsugu Ishimoto
    Hironobu Shigaki
    Keisuke Kosumi
    Naoya Yoshida
    Masayuki Watanabe
    Hideo Baba
    Journal of Gastroenterology, 2016, 51 : 520 - 530
  • [43] DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma
    Ma, Jianjuan
    Yu, Xiying
    Guo, Liping
    Lu, Shih Hsin
    ONCOLOGY LETTERS, 2013, 6 (06) : 1624 - 1630
  • [44] The LIM domain protein, CRIP2, promotes apoptosis in esophageal squamous cell carcinoma
    Lo, Paulisally Hau Yi
    Ko, Josephine Mun Yee
    Yu, Zhuo You
    Law, Simon
    Wang, Li Dong
    Li, Ji-Lin
    Srivastava, Gopesh
    Tsao, Sai Wah
    Stanbridge, Eric J.
    Lung, Maria Li
    CANCER LETTERS, 2012, 316 (01) : 39 - 45
  • [45] The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma
    Ikeguchi, M
    Sakatani, T
    Ueta, T
    Fukuda, K
    Yamaguchi, K
    Tsujitani, S
    Kaibara, N
    PATHOBIOLOGY, 2001, 69 (01) : 36 - 43
  • [46] MiR-126 promotes esophageal squamous cell carcinoma via inhibition of apoptosis and autophagy
    Li, Mingli
    Meng, Xiangli
    Li, Mingxuan
    AGING-US, 2020, 12 (12): : 12107 - 12118
  • [47] Drug repositioning for esophageal squamous cell carcinoma
    Bennett, Adam N.
    Huang, Rui Xuan
    He, Qian
    Lee, Nikki P.
    Sung, Wing-Kin
    Chan, Kei Hang Katie
    FRONTIERS IN GENETICS, 2022, 13
  • [48] Characteristics and interplay of esophageal microbiota in esophageal squamous cell carcinoma
    Lin, Zheng
    Rao, Wenqing
    Xiang, Zhisheng
    Zeng, Qiaoyan
    Liu, Shuang
    Yu, Kaili
    Zhou, Jinsong
    Wang, Jianwen
    Chen, Weilin
    Chen, Yuanmei
    Peng, Xiane
    Hu, Zhijian
    BMC CANCER, 2022, 22 (01)
  • [49] Discovery of 2,4-diaminopyrimidine derivatives as potent inhibitors of FAK capable of activating the Hippo pathway for the treatment of esophageal squamous cell carcinoma
    Wang, Xiao
    Li, Yin-Ru
    Wu, Ji
    Niu, Jin-Bo
    Song, Jian
    Zhang, Sai-Yang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 287
  • [50] Perioperative immunotherapy for esophageal squamous cell carcinoma
    Wei, Dan D.
    Fang, Jin M.
    Wang, Huan Z.
    Chen, Jian
    Kong, Shuai
    Jiang, Yan-Yi
    Jiang, Yuan
    FRONTIERS IN IMMUNOLOGY, 2024, 15